SG11201811188TA - A buffer free, acid stable low dose volume rotavirus vaccine - Google Patents
A buffer free, acid stable low dose volume rotavirus vaccineInfo
- Publication number
- SG11201811188TA SG11201811188TA SG11201811188TA SG11201811188TA SG11201811188TA SG 11201811188T A SG11201811188T A SG 11201811188TA SG 11201811188T A SG11201811188T A SG 11201811188TA SG 11201811188T A SG11201811188T A SG 11201811188TA SG 11201811188T A SG11201811188T A SG 11201811188TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- vaccine
- turkapally
- hyderabad
- valley
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 4
- 229940124859 Rotavirus vaccine Drugs 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 229940069428 antacid Drugs 0.000 abstract 1
- 239000003159 antacid agent Substances 0.000 abstract 1
- 230000001458 anti-acid effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641020675 | 2016-06-16 | ||
| PCT/IN2017/050237 WO2017216808A1 (en) | 2016-06-16 | 2017-06-13 | A buffer free, acid stable low dose volume rotavirus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811188TA true SG11201811188TA (en) | 2019-01-30 |
Family
ID=60664101
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202012281TA SG10202012281TA (en) | 2016-06-16 | 2017-06-13 | A buffer free, acid stable low dose volume rotavirus vaccine |
| SG11201811188TA SG11201811188TA (en) | 2016-06-16 | 2017-06-13 | A buffer free, acid stable low dose volume rotavirus vaccine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202012281TA SG10202012281TA (en) | 2016-06-16 | 2017-06-13 | A buffer free, acid stable low dose volume rotavirus vaccine |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11351245B2 (ko) |
| EP (1) | EP3471768A4 (ko) |
| JP (1) | JP7108549B2 (ko) |
| KR (3) | KR20190020046A (ko) |
| CN (1) | CN109562159B (ko) |
| AU (1) | AU2017285408B2 (ko) |
| BR (1) | BR112018076094A2 (ko) |
| CA (1) | CA3027703A1 (ko) |
| CO (1) | CO2019000078A2 (ko) |
| EA (1) | EA201990027A1 (ko) |
| GB (1) | GB2566244B (ko) |
| IL (1) | IL263740B2 (ko) |
| JO (1) | JOP20180124A1 (ko) |
| MA (1) | MA44557B1 (ko) |
| MX (1) | MX2018015469A (ko) |
| MY (1) | MY198419A (ko) |
| PH (1) | PH12018502650A1 (ko) |
| SG (2) | SG10202012281TA (ko) |
| TN (1) | TN2018000436A1 (ko) |
| UA (1) | UA124430C2 (ko) |
| WO (1) | WO2017216808A1 (ko) |
| ZA (1) | ZA201900176B (ko) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6616931B1 (en) | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| ES2294801T3 (es) | 1996-09-26 | 2008-04-01 | MERCK & CO., INC. | Formulaciones de vacunas contra rotavirus. |
| US6403098B1 (en) | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| EP0878541A4 (en) * | 1996-10-18 | 2001-10-17 | Univ Osaka Res Found | ROTAVIRUS ANTIGENS, VACCINES AND MEDICINES FOR DIAGNOSING ROTAVIRUS INFECTION AND METHODS OF PREPARING THE SAME |
| BRPI9912485B8 (pt) * | 1998-07-28 | 2021-05-25 | The Government Of The Us Secretary Department Of Health And Human Services | composição imunogênica multivalente |
| WO2001012797A2 (en) | 1999-08-17 | 2001-02-22 | Smithkline Beecham Biologicals S.A. | Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| JP2005038411A (ja) | 2003-06-30 | 2005-02-10 | Sony Corp | 機器認証情報組込システム、端末機器、機器認証情報処理方法、機器認証情報処理プログラム、提供サーバ、機器認証情報提供方法、機器認証情報提供プログラム、及び記憶媒体 |
| GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| GB0516944D0 (en) * | 2005-08-17 | 2005-09-28 | Glaxosmithkline Biolog Sa | Vaccine |
| BRPI0711608B8 (pt) | 2006-05-12 | 2021-05-25 | Bharat Biotech Int Ltd | composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada |
| CN101638638A (zh) * | 2008-07-29 | 2010-02-03 | 辽宁依生生物制药有限公司 | 人猪重配轮状病毒 |
| US9598676B2 (en) | 2009-07-13 | 2017-03-21 | Bharat Biotech International Limited | Composition useful as rotavirus vaccine and a method therefor |
| JP2014512410A (ja) * | 2011-04-28 | 2014-05-22 | インターナショナル メディカ ファウンデーション | 液体ワクチン調製物 |
| EP2945650B1 (en) * | 2012-04-23 | 2023-07-05 | Bharat Biotech International Limited | Rotavirus vaccine compositions and process for preparing the same |
-
2017
- 2017-06-12 MA MA44557A patent/MA44557B1/fr unknown
- 2017-06-13 BR BR112018076094-3A patent/BR112018076094A2/pt unknown
- 2017-06-13 TN TNP/2018/000436A patent/TN2018000436A1/en unknown
- 2017-06-13 CN CN201780050188.2A patent/CN109562159B/zh active Active
- 2017-06-13 KR KR1020197001395A patent/KR20190020046A/ko not_active IP Right Cessation
- 2017-06-13 MY MYPI2018002561A patent/MY198419A/en unknown
- 2017-06-13 WO PCT/IN2017/050237 patent/WO2017216808A1/en unknown
- 2017-06-13 GB GB1900562.8A patent/GB2566244B/en active Active
- 2017-06-13 EP EP17812897.1A patent/EP3471768A4/en active Pending
- 2017-06-13 CA CA3027703A patent/CA3027703A1/en active Pending
- 2017-06-13 US US16/310,039 patent/US11351245B2/en active Active
- 2017-06-13 EA EA201990027A patent/EA201990027A1/ru unknown
- 2017-06-13 SG SG10202012281TA patent/SG10202012281TA/en unknown
- 2017-06-13 SG SG11201811188TA patent/SG11201811188TA/en unknown
- 2017-06-13 AU AU2017285408A patent/AU2017285408B2/en active Active
- 2017-06-13 KR KR1020227015137A patent/KR20220063302A/ko active Application Filing
- 2017-06-13 KR KR1020237028691A patent/KR20230125863A/ko not_active Application Discontinuation
- 2017-06-13 JP JP2018565803A patent/JP7108549B2/ja active Active
- 2017-06-13 IL IL263740A patent/IL263740B2/en unknown
- 2017-06-13 MX MX2018015469A patent/MX2018015469A/es unknown
- 2017-06-13 UA UAA201900420A patent/UA124430C2/uk unknown
-
2018
- 2018-12-14 PH PH12018502650A patent/PH12018502650A1/en unknown
- 2018-12-16 JO JOP/2018/0124A patent/JOP20180124A1/ar unknown
-
2019
- 2019-01-08 CO CONC2019/0000078A patent/CO2019000078A2/es unknown
- 2019-01-10 ZA ZA2019/00176A patent/ZA201900176B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808913WA (en) | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201804961UA (en) | Formulations with reduced degradation of polysorbate | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201906616VA (en) | Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants | |
| SG11201807023QA (en) | Compositions and methods for preventing and/or treating vitamin b12 deficiency | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |